× Relationship between body mass index and bone mineral density in Mashhad, Iran; a cross-sectional Study

× Association of parathyroid hormone with plasma magnesium in health and disease; a review

× Fibroblast growth factor 23 and cardiovascular disease in chronic kidney disease; new trends

× Effect and safety of alendronate on bone density in patients with chronic kidney disease; a controlled double blind randomized clinical trial

× Estimation of annual per capita treatment in osteoporosis

× Erdheim-Chester disease; a 31-year-old woman presented with bone pain and ophthalmologic involvement: a case report

× Cinacalcet in patients with primary hyperparathyroidism; a review

× An update on prevention and treatment of osteoporosis

× Association of secondary hyperparathyroidism with anemiain patients with end-stage renal disease; a review on currentknowledge

× The need for a reliable bone biomarker to better assess chronic kidney disease mineral and bone disorder

× Challenging look at therapeutic trend of chronic kidney disease–mineral bone disorder in children

× Aggravating factors for osteoporosis; a brief overview of the current findings

× Bone mineral density and bone metabolism biochemical markers in patients with chronic kidney disease at the hemodialysis treatment

× Cinacalcet therapy for achievement of the NKF/K-DOQITM clinical practice guidelines for bone and mineral metabolism in individuals under regular hemodialysis

× Effect of sodium-glucose transporter 2 inhibitors on bone

× Diseases of the parathyroid glands in chronic kidney disease

× Hemodynamic changes and related factors in bone cement implantation syndrome in knee arthroplasty candidates

× Sclerostin in hemodialysis patients

× Impact of parathyroid hormone on osteoporosis; a short look at the current knowledge